Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced its financial results for the quarter ended June 30, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Optimer reported net loss for the second quarter of 2011 of $24.2 million, or ($0.52) per share on both a basic and diluted basis, as compared to a net loss for the second quarter of 2010 of $10.1 million, or ($0.26) per share on both a basic and diluted basis.  The increase in net loss was primarily due to increases in marketing, research and development, and general and administrative expenses related to the U.S. approval and third quarter launch of DIFICID™.

Marketing expenses for the second quarter of 2011 increased $6.3 million compared to the second quarter of 2010 due to Optimer's efforts to establish a commercial infrastructure and prepare for the launch of DIFICID, including the hiring of approximately 100 marketing and sales staff.  General and administrative expenses increased $3.8 million compared to the second quarter of 2010, primarily because of higher compensation expense due to additional headcount as well as higher recruitment, consulting, facilities and legal expenses.  Research and development expenses increased $4.2 million compared to the second quarter of 2010 due to higher health economics research, pharmacovigilance, medical affairs  and publication expenses, as well as higher research and development expenses by OBI associated with the OPT-822 Phase 2/3 trial in breast cancer.

As of June 30, 2011, Optimer held cash, cash equivalents and short-term investments of $157.8 million and had 46,602,501 shares outstanding.

"The second quarter culminated with the FDA approval of DIFICID for the treatment of C. difficile-associated diarrhea, or CDAD, in patients over the age of 18, which includes clear differentiation and superiority over oral vancomycin in sustained clinical response 25 days after the end of therapy," said Pedro Lichtinger, President and CEO of Optimer.  "Our success with the FDA approval and the recent launch of DIFICID can be attributed to thorough preparation and execution by our team. We remain highly focused on the successful introduction of DIFICID to physicians and patients, and on establishing DIFICID, based on the clinical experience to date, as the preferred treatment for CDAD patients."

Second Quarter and Recent Highlights

  • On May 27, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID™ (fidaxomicin) Tablets for the treatment of CDAD in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease.
  • On July 18, Optimer announced the commercial launch of DIFICID™ Tablets for the treatment of CDAD in patients 18 years of age and older.
  • Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID for the treatment of CDAD in the U.S. to help maximize the impact of, and de-risk, the commercial launch of DIFICID.
  • Optimer also presented additional data analysis from the DIFICID Phase 3 clinical trials highlighting risk factors associated with negative outcomes in patients with CDAD such as advanced age and immunosuppression. Data were presented at key scientific conferences including the European Congress of Clinical Microbiology and Infectious Diseases, Digestive Disease Week and the Annual Meeting of the American Geriatric Society.

  • About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Forward Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's plans to commercialize DIFICID, including with its co-promotion partner, the incidence of CDAD, and Optimer's expectations regarding the impact of the commercial launch of DIFICID. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the implementation and continuation of Optimer's co-promotion agreement with Cubist, Optimer's and Cubist's ability to commercialize DIFICID according to Optimer's expected scope and timelines, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on hospital formularies, Optimer's ability to successfully manage a sales and marketing organization and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Contacts:
    Optimer Pharmaceuticals, Inc.
    David Walsey, Vice President, Investor Relations and Corporate Communications
    858-909-0736

    Canale Communications, Inc.
    Jason I. Spark, Senior Vice President
    619-849-6005Optimer Pharmaceuticals, Inc.Consolidated Statements of Operations(unaudited) Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2011201020112010Revenues:Licensing

    $
    - $
    - $69,165,000 $
    - Research grants

    33,294357,436144,933654,873   Total revenues

    33,294357,43669,309,933654,873Cost and expenses:   Cost of licensing

    --4,273,532-Research and development

    10,570,6366,419,25119,041,14517,780,830Marketing

    6,974,322656,46410,407,915925,058General and administrative

    7,506,5253,686,44215,786,7076,075,154Total operating expenses

    25,051,48310,762,15749,509,29924,781,042Income (loss) from operations

    (25,018,189)(10,404,721)19,800,634(24,126,169)Interest income and other, net

    95,86053,719119,10278,497Consolidated net income (loss)

    $ (24,922,329)$  (10,351,002)$19,919,736$(24,047,672)Net loss attributable to noncontrolling interest

    683,483290,105974,288491,020Net income (loss) attributable to Optimer Pharmaceuticals, Inc.

    $ (24,238,846)$  (10,060,897)$20,894,024$(23,556,652)Net income (loss) per share - basic

    $
    (0.52)$
    (0.26)$
    .47$
    (0.64)Net income (loss) per share - diluted

    $
    (0.52)$
    (0.26)$
    .46$
    (0.64)Weighted average number of shares used to compute net  income (loss) per share - basic

    46,479,39538,306,91044,581,01036,663,380Weighted average number of shares used to compute net  income (loss) per share - diluted

    46,479,39538,306,91045,447,26136,663,380Optimer Pharmaceuticals, Inc.Condensed Consolidated Balance SheetsJune 30December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $   61,402,529$   19,861,924Short-term investments

    96,391,74229,553,506Research grant and other  receivables

    78,95753,552Inventory

    1,369,482-Prepaid expenses and other current assets

    5,843,511463,307Total current assets

    165,086,22149,932,289Property and equipment, net

    2,172,443697,683Long-term investments

    882,000882,000Other assets

    1,242,523508,190Total assets

    $ 169,383,187$   52,020,162LIABILITIES  AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable

    $
    ,738,492$
    2,307,820Accrued expenses

    5,080,6792,385,046Total current liabilities

    11,819,1714,692,866Deferred rent

    183,515141,138Stockholders’ equity

    157,380,50147,186,158Total liabilities and stockholders’ equity

    $ 169,383,187$   52,020,162
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
    2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
    4. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
    5. Optimer Pharmaceuticals Expands Senior Management Team
    6. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
    7. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
    8. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
    9. Trading Halted Today in Optimer Pharmaceuticals Stock
    10. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
    11. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
    (Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
    (Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
    (Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
    (Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
    Breaking Medicine News(10 mins):